Cox Regression Analysis of Overall Survival and Progression-Free Survival of 165 Primary Glioblastoma Patients With Substratification by MGMT Values
| . | OS MGMT (<2 vs ≥2 vs 1.11-1.99) Hazard Ratio (95% CI), P Value . | PFS MGMT(<2 vs ≥2 vs 1.11-1.99) Hazard Ratio (95% CI), P Value . | OS MGMT(<2 vs ≥2 vs 1.11-1.99) Hazard Ratio (95% CI), P Value . | PFS MGMT(<2 vs ≥2 vs 1.11-1.99) Hazard Ratio (95% CI), P Value . | |
|---|---|---|---|---|---|
| Age at Diagnosis | 1.020 (0.999-1.042), P = .059 | 1.020 (1.001-1.039), P = .040 | 1.020 (0.999-1.042), P = .059 | 1.020 (1.001-1.039), P = .040 | |
| KPS | 1.002 (0.979-1.024), P = .892 | 0.988 (0.969-1.008), P = .234 | 1.002 (0.979-1.024), P = .892 | 0.988 (0.969-1.008), P = .234 | |
| Gender Male vs female | 1.714 (1.069-2.746), P = .025 | 1.479 (0.991-2.206), P = .055 | 1.714 (1.069 - 2.746), P = .025 | 1.479 (0.991-2.206), P = .055 | |
| Resection STR and Bx vs GTR | 1.025 (0.657-1.599), P = .913 | 1.063 (0.729-1.549), P = .751 | 1.025 (0.657-1.599), P = .913 | 1.063 (0.729-1.549), P = .751 | |
| MGMT | ≥2 | 0.429 (0.262-0.702), P = .001 | 0.303 (0.197-0.465), P < .001 | Reference | Reference |
| <2 | Reference | Reference | 2.333 (1.424-3.822), P = .001 | 3.305 (2.151-5.077), P < .001 | |
| 1-1.99 | 0.442 (0.186-1.050), P = .064 | 0.360 (0.169-0.765), P = .008 | 1.031 (0.418-2.539), P = .948 | 1.189 (0.549-2.574), P = .661 | |
| . | OS MGMT (<2 vs ≥2 vs 1.11-1.99) Hazard Ratio (95% CI), P Value . | PFS MGMT(<2 vs ≥2 vs 1.11-1.99) Hazard Ratio (95% CI), P Value . | OS MGMT(<2 vs ≥2 vs 1.11-1.99) Hazard Ratio (95% CI), P Value . | PFS MGMT(<2 vs ≥2 vs 1.11-1.99) Hazard Ratio (95% CI), P Value . | |
|---|---|---|---|---|---|
| Age at Diagnosis | 1.020 (0.999-1.042), P = .059 | 1.020 (1.001-1.039), P = .040 | 1.020 (0.999-1.042), P = .059 | 1.020 (1.001-1.039), P = .040 | |
| KPS | 1.002 (0.979-1.024), P = .892 | 0.988 (0.969-1.008), P = .234 | 1.002 (0.979-1.024), P = .892 | 0.988 (0.969-1.008), P = .234 | |
| Gender Male vs female | 1.714 (1.069-2.746), P = .025 | 1.479 (0.991-2.206), P = .055 | 1.714 (1.069 - 2.746), P = .025 | 1.479 (0.991-2.206), P = .055 | |
| Resection STR and Bx vs GTR | 1.025 (0.657-1.599), P = .913 | 1.063 (0.729-1.549), P = .751 | 1.025 (0.657-1.599), P = .913 | 1.063 (0.729-1.549), P = .751 | |
| MGMT | ≥2 | 0.429 (0.262-0.702), P = .001 | 0.303 (0.197-0.465), P < .001 | Reference | Reference |
| <2 | Reference | Reference | 2.333 (1.424-3.822), P = .001 | 3.305 (2.151-5.077), P < .001 | |
| 1-1.99 | 0.442 (0.186-1.050), P = .064 | 0.360 (0.169-0.765), P = .008 | 1.031 (0.418-2.539), P = .948 | 1.189 (0.549-2.574), P = .661 | |
Abbreviations: Bx, biopsy; CI, confidence interval; GTR, gross total resection; KPS, Karnofsky Performance Status; MGMT: O6-methylguanine-DNA methyltransferase; OS, overall survival; PFS, progression-free survival; STR, subtotal resection.
Cox Regression Analysis of Overall Survival and Progression-Free Survival of 165 Primary Glioblastoma Patients With Substratification by MGMT Values
| . | OS MGMT (<2 vs ≥2 vs 1.11-1.99) Hazard Ratio (95% CI), P Value . | PFS MGMT(<2 vs ≥2 vs 1.11-1.99) Hazard Ratio (95% CI), P Value . | OS MGMT(<2 vs ≥2 vs 1.11-1.99) Hazard Ratio (95% CI), P Value . | PFS MGMT(<2 vs ≥2 vs 1.11-1.99) Hazard Ratio (95% CI), P Value . | |
|---|---|---|---|---|---|
| Age at Diagnosis | 1.020 (0.999-1.042), P = .059 | 1.020 (1.001-1.039), P = .040 | 1.020 (0.999-1.042), P = .059 | 1.020 (1.001-1.039), P = .040 | |
| KPS | 1.002 (0.979-1.024), P = .892 | 0.988 (0.969-1.008), P = .234 | 1.002 (0.979-1.024), P = .892 | 0.988 (0.969-1.008), P = .234 | |
| Gender Male vs female | 1.714 (1.069-2.746), P = .025 | 1.479 (0.991-2.206), P = .055 | 1.714 (1.069 - 2.746), P = .025 | 1.479 (0.991-2.206), P = .055 | |
| Resection STR and Bx vs GTR | 1.025 (0.657-1.599), P = .913 | 1.063 (0.729-1.549), P = .751 | 1.025 (0.657-1.599), P = .913 | 1.063 (0.729-1.549), P = .751 | |
| MGMT | ≥2 | 0.429 (0.262-0.702), P = .001 | 0.303 (0.197-0.465), P < .001 | Reference | Reference |
| <2 | Reference | Reference | 2.333 (1.424-3.822), P = .001 | 3.305 (2.151-5.077), P < .001 | |
| 1-1.99 | 0.442 (0.186-1.050), P = .064 | 0.360 (0.169-0.765), P = .008 | 1.031 (0.418-2.539), P = .948 | 1.189 (0.549-2.574), P = .661 | |
| . | OS MGMT (<2 vs ≥2 vs 1.11-1.99) Hazard Ratio (95% CI), P Value . | PFS MGMT(<2 vs ≥2 vs 1.11-1.99) Hazard Ratio (95% CI), P Value . | OS MGMT(<2 vs ≥2 vs 1.11-1.99) Hazard Ratio (95% CI), P Value . | PFS MGMT(<2 vs ≥2 vs 1.11-1.99) Hazard Ratio (95% CI), P Value . | |
|---|---|---|---|---|---|
| Age at Diagnosis | 1.020 (0.999-1.042), P = .059 | 1.020 (1.001-1.039), P = .040 | 1.020 (0.999-1.042), P = .059 | 1.020 (1.001-1.039), P = .040 | |
| KPS | 1.002 (0.979-1.024), P = .892 | 0.988 (0.969-1.008), P = .234 | 1.002 (0.979-1.024), P = .892 | 0.988 (0.969-1.008), P = .234 | |
| Gender Male vs female | 1.714 (1.069-2.746), P = .025 | 1.479 (0.991-2.206), P = .055 | 1.714 (1.069 - 2.746), P = .025 | 1.479 (0.991-2.206), P = .055 | |
| Resection STR and Bx vs GTR | 1.025 (0.657-1.599), P = .913 | 1.063 (0.729-1.549), P = .751 | 1.025 (0.657-1.599), P = .913 | 1.063 (0.729-1.549), P = .751 | |
| MGMT | ≥2 | 0.429 (0.262-0.702), P = .001 | 0.303 (0.197-0.465), P < .001 | Reference | Reference |
| <2 | Reference | Reference | 2.333 (1.424-3.822), P = .001 | 3.305 (2.151-5.077), P < .001 | |
| 1-1.99 | 0.442 (0.186-1.050), P = .064 | 0.360 (0.169-0.765), P = .008 | 1.031 (0.418-2.539), P = .948 | 1.189 (0.549-2.574), P = .661 | |
Abbreviations: Bx, biopsy; CI, confidence interval; GTR, gross total resection; KPS, Karnofsky Performance Status; MGMT: O6-methylguanine-DNA methyltransferase; OS, overall survival; PFS, progression-free survival; STR, subtotal resection.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
